Evidence against a vasopressor role of ADH in malignant DOC-salt hypertension.
To investigate the possible role of vasopressin (VP) in the maintenance of DOC-salt hypertension the effect of two VP pressor antagonists on mean arterial pressure and the pressor responsiveness to exogenous VP were studied in conscious, freely moving rats with malignant DOC-salt hypertension. Intravenous injections of either 20 micrograms/kg of dP Tyr(Me)AVP or 10 micrograms/kg of d(CH2)5Tyr(Me)AVP had no significant effect on mean arterial pressure and heart rate, although both antagonists almost completely abolished the pressor response to VP. Furthermore, the animals with DOC-salt hypertension exhibited decreased pressor responsiveness to exogenous VP. The present findings strongly suggest that VP is not essential as a pressor hormone for maintaining blood pressure in malignant DOC-salt hypertension.
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology; D003900:Desoxycorticosterone / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005260:Female; D006974:Hypertension, Malignant / Q000503:physiopathology*; D051381:Rats; D012965:Sodium Chloride / Q000633:toxicity; D014667:Vasopressins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000502:physiology*
D014667:Vasopressins; D001127:Arginine Vasopressin; D003900:Desoxycorticosterone; D012965:Sodium Chloride; C028888:argipressin, deaminopenicillamine(1)-O-methyl-Tyr(2)-; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-